Indeed, inhibition of PI3K [7], AKT [8] and mTOR [1] has been shown promising results in vitro and in xenograft models and led to the clinical trials to examine an efficiency against IM-resistant GIST. This evidence concerns the gene AKT1 and gastrointestinal stromal tumor.